COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence

Current Opinion in Investigational Drugs

Volumn 11, Issue 1, 2010, Pages 31-42

  Müller, Norbert ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

COX 2; Depression; Glutamate; Inflammation; Psychoneuroimmunology; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; CELECOXIB; CIMICOXIB; CLOZAPINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSERINE; CYTOKINE; DIZOCILPINE; FLUOXETINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; KETAMINE; MEMANTINE; MILACEMIDE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PARECOXIB; PHENCYCLIDINE; PLACEBO; PROSTAGLANDIN E2; REBOXETINE; RILUZOLE; RISPERIDONE; ROFECOXIB; SEROTONIN; UNINDEXED DRUG;

ADD ON THERAPY; BIPOLAR DEPRESSION; CLINICAL TRIAL; COMPETITIVE INHIBITION; DEPRESSION; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR DEPRESSION; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NEUROIMMUNOLOGY; NEUROTRANSMISSION; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DEPRESSIVE DISORDER; GLUTAMIC ACID; HUMANS; INFLAMMATION; KYNURENINE; PROSTAGLANDINS; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 74549220751     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Lopez AD, Murray CC: The global burden of disease. 1990-2020. Nat Med (1998) 4(11):1241-1243.
2. Müller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Mol Psychiatry (2007) 12(11):988-1000.
3. Müller N, Schwarz MJ: The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view. J Neural Transm Suppl (2007) (72):269-280.
4. Matussek N: Neurobiologie und Depression. Med Monatsschr (1966) 3:109-112.
5. Coppen A, Swade C: 5-HT and depression: The present position. In: New concepts in depression. Briley M, Fillion G (Eds), MacMillan Press, London, UK (1988):120-136.
6. Yan QS, Reith ME, Jobe PC, Dailey JW: Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res (1997) 765(1):149-158.
7. Martin P, Carlsson ML, Hjorth S: Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats. Neuroreport (1998) 9(13):2985-2988.
8. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr (1982) 232(4):299-304.
9. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F: Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry (1993) 150(11):1731-1733.
10. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, Invernizzi G: Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology (1998) 37(3):124-129.
11. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand (1998) 97(4):302-308.
12. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF: Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 61(7):705-713.
13. Nowak G, Ordway GA, Paul IA: Alterations in the N-methyl-daspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res (1995) 675(1-2):157-164.
14. Nudmamud-Thanoi S, Reynolds GP: The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett (2004) 372(1-2):173-177.
15. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B: Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord (2003) 5(4):257-264.
16. Maj J, Rogóz Z, Skuza G, Sowínska H: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur Neuropsychopharmacol (1992) 2(1):37-41.
17. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 185(1):1-10.
18. Yilmaz A, Schulz D, Aksoy A, Canbeyli R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav (2002) 71(1-2):341-344.
19. Ossowska G, Klenk-Majewska B, Szymczyk G: The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J Physiol Pharmacol (1997) 48(1): 127-135.
20. Crane GE: Cyloserine as an antidepressant agent. Am J Psychiatry (1959) 115(11):1025-1026.
21. Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. Pharmacopsychiatry (1999) 32(2):47-55.
22. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L, Rosenzcwaig S, Weizman A: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol (2003) 18(2):93-96.
23. Kudoh A, Takahira Y, Katagai H, Takazawa T: Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg (2002) 95(1):114-118.
24. Ostroff R, Gonzales M, Sanacora G: Antidepressant effect of ketamine during ECT. Am J Psychiatry (2005) 162(7):1385-1386.
25. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO: Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol (2004) 24(1):123-128.
26. Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH: Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (2003) 167(2):219-220.
27. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH: Riluzole augmentation for treatment-resistant depression. Am J Psychiatry (2004) 161(11):2132.
28. Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1988) 1(3):179-186.
29. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML: Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol (2001) 41:237-260.
30. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett (1980) 20(3): 379-382.
31. Miller DW, Abercrombie ED: Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull (1996) 40(1):57-62.
32. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM et al: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad Sci USA (1996) 93(17):9235-9240.
33. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51(3):199-214.
34. Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry (1995) 52(12):998-1007.
35. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY: Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: Relation to negative symptoms. Int J Neuropsychopharmacol (2004) 7(1):1-8.
36. Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY: Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol (2005) 8(3):451-455.
37. Tamminga CA, Cascella N, Fakouhl TD, Hertin RL: Enhancement of NMDA-mediated transmission in schizophrenia: Effects of milacemide. In: Novel Antipsychotic Drugs. Meltzer HY (Ed), Raven Press, New York, NY, USA (1992):171-177.
38. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry (1999) 56(1):29-36.
39. Dantzer R, O'Conner JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neureosci (2008) 9(1): 46-56.
40. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 58(5): 445-452.
41. Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R: Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-α and IL-6 secretion. Psychoneuroendocrinology (2002) 27(8):945-956.
42. Song C, Leonard BE (Eds): Fundamentals of Psychoneuroimmunology. J Wiley and Sons, New York, NY, USA (2000).
43. Besedovsky H, del Rey A, Sorkin E, De Prada M, Burri R, Honegger C: The immune response evokes changes in brain noradrenergic neurons. Science (1983) 221(4610):564-566.
44. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res (1994) 643(1-2):40-49.
45. Schwarz MJ, Chiang S, Müller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun (2001) 15(4):340-370.
46. Myint AM, Kim YK: Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med Hypotheses (2003) 61(5-6):519-525.
47. Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche BV, Cosyns P: Increased neopterin and interferon-γsecretion and lower availability of l-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res (1994) 54(2):143-160.
48. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Kynurenine pathway in major depression: Evidence of impaired neuroprotection. J Affect Disord (2007) 98(1-2):143-151.
49. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP, Susser ES: Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry (2004) 61(8):774-780.
50. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH: Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry (2001) 58(11):1032-1037.
51. Westergaard T, Mortensen PB, Pedersen CB, Wohlfahrt J, Melbye M: Exposure to prenatal and childhood infections and the risk of schizophrenia: Suggestions from a study of sibship characteristics and influenza prevalence. Arch Gen Psychiatry 1999) 56(11):993-998.
52. Zuckerman L, Weiner I: Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res (2005) 39(3):311-323.
53. Gattaz WF, Abrahao AL, Foccacia R: Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci (2004) 254(1):23-26.
54. Koponen H, Rantakallio P, Veijola J, Jones P, Jokelainen J, Isohanni M: Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 254(1): 9-13.
55. Brown AS: The risk for schizophrenia from childhood and adult infections. Am J Psychiatry (2008) 165(1):7-10.
56. Dalman C, Allebeck P, Gunnell D, Harrison G, Kristensson K, Lewis G, Lofving S, Rasmussen F, Wicks S, Karlsson H: Infections in the CNS during childhood and the risk of subsequent psychotic illness: A cohort study of more than one million Swedish subjects. Am J Psychiatry (2008) 165(1):59-65.
57. Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R: Investigations of the cellular immunity during depression and the free interval: Evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry (1993) 17(5):713-730.
58. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 34(4):301-309.
59. Maes M, Meltzer HY, Buckley P, Bosmans E: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci (1995) 244(6):325-329.
60. Irwin M: Immune correlates of depression. Adv Exp Med Biol (1999) 461:1-24.
61. Nunes SO, Reiche EM, Morimoto HK, Matsuo T, Itano EN, Xavier EC, Yamashita CM, Vieira VR, Menoli AV, Silva SS, Costa FB et al: Immune and hormonal activity in adults suffering from depression. Braz J Med Biol Res (2002) 35(5):581-587.
62. Müller N, Schwarz MJ: Immunology in anxiety and depression. In: Handbook of Depression and Anxiety, 2nd edition. Kasper S, den Boer JA, Sitsen JMA (Eds), Marcel Dekker, New York, NY, USA (2002): 267-288.
63. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M: Increased serum tumor necrosis factor α concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 11(3):203-208.
64. Herbert TB, Cohen S: Depression and immunity: A meta-analytic review. Psychol Bull (1993) 113(3):472-486.
65. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand (1996) 94(3):198-204.
66. Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H: Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci (2001) 251(2):90-97.
67. Sperner-Unterweger B, Miller C, Holzner B, Widner B, Fleischhacker WW, Fuchs D: Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Psychiatry, Psychoimmunology, and viruses. Müller NW (Ed), Springer, New York, NY, USA (1999):115-119.
68. Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC: Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res (1984) 11(2):83-89.
69. Dunbar PR, Hill J, Neale TJ, Mellsop GW: Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med (1992) 22(4):1051-1057.
70. Bonaccorso S, Lin AH, Verkerk R, van Hunsel F, Libbrecht I, Scharpe S, DeClerck L, Biondi M, Janca A, Maes M: Immune markers in fibromyalgia: Comparison with major depressed patients and normal volunteers. J Affect Disord (1998) 48(1):75-82.
71. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res (1993) 49(1):11-27.
72. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry (2005) 29(2):201-217.
73. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol (1996) 78(1): 83-85.
74. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatry Res (1996) 64(3):161-167.
75. Körschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Müller N: Fibrin degradation products in post mortem brain tissue of schizophrenics: A possible marker for underlying inflammatory processes. Schizophr Res (1996) 19(2-3):103-109.
76. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci (1996) 246(5):279-284.
77. Müller N, Riedel M, Ackenheil M, Schwarz MJ: Cellular and humoral immune system in schizophrenia: A conceptual re-evaluation. World J Biol Psychiatry (2000) 1(4):173-179.
78. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R: Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res (1991) 37(2):147-160.
79. Schwarz MJ, Riedel M, Ackenheil M, Müller N: Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry (2000) 47(1):29-33.
80. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res (1999) 33(5):407-418.
81. Molholm HB: Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr Quarterly (1942) 16(3):565-571.
82. Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, Müller N: Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res (2006) 41(1-2):3-7.
83. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry (2008) 63(8):801-808.
84. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, Clerici M: Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry (1998) 22(6):947-957.
85. van Kammen DP, McAllister-Sistilli CG, Kelley ME: Relationship between immune and behavioral measures in schizophrenia. In: Current Update in Psychoimmunology. Wieselmann GW (Ed), Springer, New York, NY, USA (1997):51-55.
86. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM: Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol (1997) 159(6):2994-2999.
87. Alberati GD, Ricciardi CP, Kohler C, Cesura AM: Regulation of the kynurenine metabolic pathway by interferon-γ in murine cloned macrophages and microglial cells. J Neurochem (1996) 66(3):996-1004.
88. Mellor AL, Munn DH: Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today (1999) 20(10):469-473.
89. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 189(9):1363-1372.
90. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D: Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol (1999) 116(3):435-440.
91. Robinson CM, Hale PT, Carlin JM: The role of IFN-? and TNF-α- responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res (2005) 25(1):20-30.
92. Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN: CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry (1983) 40(4):405-406.
93. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M: Increased depressive ratings in patients with hepatitis C receiving interferon-γ-based immunotherapy are related to interferon-γ-induced changes in the serotonergic system. J Clin Psychopharmacol (2002) 22(1): 86-90.
94. Myint AM, Leonard BE, Steinbusch HW, Kim YK: Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord (2005) 88(2):167-173.
95. Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev (1993) 45(3):309-379.
96. Schwarcz R, Pellicciari R: Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther (2002) 303(1):1-10.
97. Kessler M, Terramani T, Lynch G, Baudry M: A glycine site associated with N-methyl-d-aspartic acid receptors: Characterization and identification of a new class of antagonists. J Neurochem (1989) 52(4):1319-1328.
98. 7 nicotinic receptor expression: Physiopathological implications. J Neurosci (2001) 21(19):7463-7473.
99. Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson- Todd LK, Schwieler L, Olsson E, Larsson K, Engberg G, Erhardt S: Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: Implications for schizophrenia. Int J Neuropsychopharmacol (2009) 12(4):501-512.
100. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G: The kynurenic acid hypothesis of schizophrenia. Physiol Behav (2007) 92(1-2):203-209.
101. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S: Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 80(2-3):315-322.
102. Kaiya H, Uematsu M, Ofuji M, Nishida A, Takeuchi K, Nozaki M, Idaka E: Elevated plasma prostaglandin E2 levels in schizophrenia. J Neural Transm (1989) 77(1):39-46.
103. Das I, Khan NS: Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot Essent Fatty Acids (1998) 58(3):165-168.
104. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Whelan A, Cosyns P, De Jongh R et al: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord (1998) 49(3):211-219.
105. Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O: Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry (1988) 23(4):326-334.
106. Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A, Subichin S, Krupp NE: Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res (1986) 17(1): 41-47.
107. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M: Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum (1999) 42(12):2561-2568.
108. Litteljohn D, Mangano EN, Hayley S: Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and comorbid anxiety provoked by paraquat adminisgtration in mice. Eur J Neurosci (2008) 28(4):707-716.
109. Aid S, Langenbach R, Bosetti F: Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation (2008) 19:5-17.
110. Casolini P, Catalani A, Zuena AR, Angelucci L: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res (2002) 68(3):337-343.
111. Hu F, Wang X, Pace TW, Wu H, Miller AH: Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry (2005) 10(5):426-428.
112. Cao C, Matsumura K, Ozaki M, Watanabe Y: Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J Neurosci (1999) 19(2):716-725.
113. Sandrini M, Vitale G, Pini LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res (2002) 51(3):154-159.
114. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest (1996) 97(11):2672-2679.
115. Salzberg-Brenhouse HC, Chen EY, Emerich DF, Baldwin S, Hogeland K, Ranelli S, Lafreniere D, Perdomo B, Novak L, Kladis T, Fu K et al: Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther (2003) 306(1):218-228.
116. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation (2007) 14(2):65-71.
117. Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F, Kriwin P, Mendlewicz J: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol (2006) 21(4):219-225.
118. Collantes-Esteves E, Fernandez-Perrez Ch: Improved self-control of ostheoarthritis pain and self-reported health status in nonresponders to celecoxib switched to rofecoxib: Results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin (2003) 19(5):402-410.
119. Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein- Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ et al: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 11(7):680-684.
120. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol (2006) 21(4):227-231.
121. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress Anxiety (2009) 26(7):607-611.
122. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC: Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol (2008) 23(2):87-94.
123. Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender N, Fischer B, Sperling S, Stawicki S, Wiedl A et al: Episodespecific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med (2008) 14(9-10):546-552.
124. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 159(6):1029-1034.
125. Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: Regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol (2000) 74(12):5740-5745.
126. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 164(1):361-370.
127. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol (2002) 23(3):144-150.
128. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX, Hofig A, Dennis MA, Fuller K, Cook R, Schatz D et al: Aberrant prostaglandin synthase 2 expression defines an antigenpresenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest (1999) 104(4):515-523.
129. Schwieler L, Erhardt S, Erhardt C, Engberg G: Prostaglandinmediated control of rat brain kynurenic acid synthesis - Opposite actions by COX-1 and COX-2 isoforms. J Neural Transm (2005) 112(7):863-872.
130. Müller N, Riedel M, Dehning S, Spellmann I, Müller-Arends A, Cerovecki A, Goldstein-Mueller B, Moeller HJ, Schwarz M: Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology (2004) 29(Suppl S1):S176.
131. Müller N, Riedel M, Schwarz MJ, Engel RR: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2005) 255(2):149-151.
132. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M: COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci (2004) 254(1):14-22.
133. Zhang Y, Chun Chen D, Long Tan Y, Zhou DF: A double-blind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2006) 256(Suppl 2):II/50.
134. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B: Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res (2007) 90(1-3):179-185.
135. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D: Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry (2005) 57(12):1594-1596.
136. Rappard F, Müller N: Celecoxib add-on therapy does not have beneficial antipsychotic effects over Risperidone alone in Schizophrenia. Neuropsychopharmacology (2004) 29(Suppl S1): S222.